MX2010004046A - Compuestos novedosos de mimeticos de giro inverso y su uso (3). - Google Patents

Compuestos novedosos de mimeticos de giro inverso y su uso (3).

Info

Publication number
MX2010004046A
MX2010004046A MX2010004046A MX2010004046A MX2010004046A MX 2010004046 A MX2010004046 A MX 2010004046A MX 2010004046 A MX2010004046 A MX 2010004046A MX 2010004046 A MX2010004046 A MX 2010004046A MX 2010004046 A MX2010004046 A MX 2010004046A
Authority
MX
Mexico
Prior art keywords
reverse
novel compounds
prodrugs
reverse turn
compounds
Prior art date
Application number
MX2010004046A
Other languages
English (en)
Inventor
Jae Uk Chung
Hee-Kyung Jung
Kyung-Yun Jung
Min-Wook Jeong
Hyun-Ju La
Original Assignee
Choongwae Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharma Corp filed Critical Choongwae Pharma Corp
Publication of MX2010004046A publication Critical patent/MX2010004046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen compuestos conformacionalmente restringidos que son novedosos e imitan la estructura secundaria de regiones de giro inverso de péptidos y proteínas biológicamente activos, y que tienen una estructura bicíclica sí como sus profármacos. Dichas estructuras miméticas de giro inverso y dichos profármacos tienen utilidad en una amplia variedad de campos, incluyendo su uso como agentes de diagnostico y terapéuticos. La invención se refiere también al uso de dichos compuestos para la preparación de un medicamento para tratar o prevenir el cáncer, incluyendo una leucemia mieloide aguda.
MX2010004046A 2007-10-15 2008-10-15 Compuestos novedosos de mimeticos de giro inverso y su uso (3). MX2010004046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/974,941 US7671054B1 (en) 2001-10-12 2007-10-15 Reverse-turn mimetics and method relating thereto
PCT/KR2008/006070 WO2009051397A2 (en) 2007-10-15 2008-10-15 Novel compounds of reverse turn mimetics and the use thereof (3)

Publications (1)

Publication Number Publication Date
MX2010004046A true MX2010004046A (es) 2010-06-25

Family

ID=40567948

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010004046A MX2010004046A (es) 2007-10-15 2008-10-15 Compuestos novedosos de mimeticos de giro inverso y su uso (3).
MX2010004045A MX2010004045A (es) 2007-10-15 2008-10-15 Compuestos novedosos de mimeticos de giro inverso, y su uso (1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010004045A MX2010004045A (es) 2007-10-15 2008-10-15 Compuestos novedosos de mimeticos de giro inverso, y su uso (1).

Country Status (13)

Country Link
US (4) US7671054B1 (es)
EP (3) EP2212328B1 (es)
JP (3) JP5400785B2 (es)
KR (3) KR101229504B1 (es)
CN (4) CN101827849B (es)
AU (2) AU2008312193B2 (es)
BR (2) BRPI0818647B1 (es)
CA (2) CA2702461C (es)
ES (3) ES2541459T3 (es)
MX (2) MX2010004046A (es)
PL (1) PL2212330T3 (es)
RU (2) RU2457210C2 (es)
WO (3) WO2009051398A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
JP5536336B2 (ja) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
KR101671535B1 (ko) * 2008-06-06 2016-11-01 가부시키가이샤 프리즘 파마 알파 나선 모방체 및 이와 관련된 방법
CN102186853A (zh) 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
US20100267672A1 (en) * 2009-04-15 2010-10-21 Choongwae Pharma Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
US9040531B2 (en) 2009-05-07 2015-05-26 Prism BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
WO2011096440A1 (ja) 2010-02-03 2011-08-11 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 天然変性タンパク質に結合する化合物およびそのスクリーニング方法
KR102168006B1 (ko) 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
WO2012050393A2 (ko) * 2010-10-14 2012-04-19 제이더블유중외제약 주식회사 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
ES2935544T3 (es) 2010-11-16 2023-03-07 Univ Southern California Antagonistas de CBP/catenina para aumentar la división asimétrica de células madre somáticas
US20140051706A1 (en) * 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto
US20140005164A1 (en) * 2011-04-04 2014-01-02 Siena Biotech S.P.A. Wnt pathway antagonists
KR101441406B1 (ko) * 2011-05-25 2014-11-04 주식회사 바이오이미징코리아 디아릴이오도늄 염 전구체를 이용한 플로오린-18이 표지된 플루마제닐의 제조 방법
ES2577863T3 (es) * 2011-08-09 2016-07-19 Jw Pharmaceutical Corporation Composición para la prevención y el tratamiento del cáncer de pulmón de células no pequeñas, que contiene derivados de pirazino-triazina
US9353119B2 (en) * 2011-08-09 2016-05-31 Jw Pharmaceutical Corporation Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2763995A4 (en) 2011-10-07 2015-05-27 Univ Southern California CBP / CATENIN ANTAGONISTS FOR IMPROVING ASYMMETRIC DIVISION OF BODY STEM CELLS
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CA2923530A1 (en) * 2013-09-11 2015-03-19 Prism Pharma Co., Ltd. Method of producing pyrazino[2,1-c][1,2,4]triazine compound
US9174998B2 (en) 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
RU2723551C2 (ru) * 2015-06-23 2020-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
CN108026104B (zh) * 2015-09-18 2021-06-18 国立大学法人鸟取大学 利用低分子化合物的癌及纤维化的抑制和再生促进的效果
WO2017184808A1 (en) * 2016-04-20 2017-10-26 University Of Southern California Compounds and methods for increasing hematopoiesis
CN110950873A (zh) * 2019-12-10 2020-04-03 河南大学 坡尔吲哚的合成新方法
TW202200582A (zh) 2020-03-12 2022-01-01 美商3+2製藥公司 Cbp/連環蛋白訊息傳遞路徑抑制劑及其用途
WO2023027888A1 (en) * 2021-08-26 2023-03-02 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3120859A1 (de) 1981-05-26 1982-12-23 Basf Ag, 6700 Ludwigshafen Dihalogenacetamide, verfahren zu ihrer herstellung und herbizide mittel, die acetanilide als herbizide wirkstoffe und diese dihalogenacetamide als antagonistische mittel enthalten
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2141447A1 (en) 1992-08-06 1994-02-17 Michael Kahn Conformationally restricted mimetics of reverse turns and peptides containing the same
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5693325A (en) 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US6245764B1 (en) 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6020331A (en) 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6117896A (en) 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
WO1998005333A1 (en) 1996-08-05 1998-02-12 Molecumetics Ltd. Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
US6451972B1 (en) 1998-11-16 2002-09-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US6872825B2 (en) 1999-12-21 2005-03-29 The Procter & Gamble Company Peptide β-turn mimetic compounds and processes for making them
DE10005631A1 (de) 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
JP2004534097A (ja) 2001-07-09 2004-11-11 フアルマシア・イタリア・エツセ・ピー・アー ＴＣＦ−４とβ−カテニンの相互作用阻害剤
WO2003030907A1 (en) * 2001-10-09 2003-04-17 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ATE398129T1 (de) * 2001-10-12 2008-07-15 Choongwae Pharma Corp Reverse-turn-mimetika und diese betreffendes verfahren
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
JP2006517551A (ja) 2003-02-13 2006-07-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 窒素置換ヘキサヒドロピラジノ［１，２−ａ］ピリミジン−４，７−ジオン誘導体、その製造方法および医薬としてのその使用
AU2004212042A1 (en) 2003-02-13 2004-08-26 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments
US7531320B2 (en) 2003-08-28 2009-05-12 Choongwae Pharma Corporation Modulation of β-catenin/TCF-activated transcription
JP5536336B2 (ja) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
CA2632370A1 (en) 2005-11-28 2007-05-31 Choongwae Pharma Corporation Serum-free expansion of cells in culture
KR101671535B1 (ko) 2008-06-06 2016-11-01 가부시키가이샤 프리즘 파마 알파 나선 모방체 및 이와 관련된 방법

Also Published As

Publication number Publication date
US20100240662A1 (en) 2010-09-23
US8049008B2 (en) 2011-11-01
WO2009051398A2 (en) 2009-04-23
EP2212329A2 (en) 2010-08-04
JP2011500667A (ja) 2011-01-06
BRPI0818511A2 (pt) 2015-06-16
EP2212330A2 (en) 2010-08-04
ES2541459T3 (es) 2015-07-20
AU2008312193A1 (en) 2009-04-23
MX2010004045A (es) 2010-07-06
RU2010119468A (ru) 2011-11-27
CN101827850A (zh) 2010-09-08
US7671054B1 (en) 2010-03-02
US8138337B2 (en) 2012-03-20
EP2212328B1 (en) 2017-01-25
AU2008312191A1 (en) 2009-04-23
ES2622703T3 (es) 2017-07-07
JP2011500666A (ja) 2011-01-06
EP2212329A4 (en) 2011-11-30
JP5222949B2 (ja) 2013-06-26
CN101827849A (zh) 2010-09-08
CN101827849B (zh) 2013-07-24
EP2212328A2 (en) 2010-08-04
WO2009051398A3 (en) 2009-06-04
BRPI0818647B1 (pt) 2021-10-26
CA2702461C (en) 2012-12-11
RU2010119447A (ru) 2011-11-27
EP2212330A4 (en) 2011-11-30
WO2009051399A3 (en) 2009-06-04
JP5222948B2 (ja) 2013-06-26
KR101269420B1 (ko) 2013-05-30
CN101827850B (zh) 2014-03-12
CA2702461A1 (en) 2009-04-23
US8071764B2 (en) 2011-12-06
CN101896485A (zh) 2010-11-24
WO2009051397A3 (en) 2009-06-04
KR20100085107A (ko) 2010-07-28
ES2509042T3 (es) 2014-10-16
RU2457210C2 (ru) 2012-07-27
US20100228027A1 (en) 2010-09-09
JP5400785B2 (ja) 2014-01-29
WO2009051397A2 (en) 2009-04-23
US20100222303A1 (en) 2010-09-02
CN103539797B (zh) 2016-05-18
KR20100085102A (ko) 2010-07-28
PL2212330T3 (pl) 2015-09-30
EP2212329B1 (en) 2014-07-30
KR101542921B1 (ko) 2015-08-11
CA2701735A1 (en) 2009-04-23
AU2008312191B2 (en) 2012-07-05
CN103539797A (zh) 2014-01-29
KR20100099116A (ko) 2010-09-10
BRPI0818647A2 (pt) 2015-04-07
RU2470024C2 (ru) 2012-12-20
EP2212328A4 (en) 2011-11-30
WO2009051399A2 (en) 2009-04-23
WO2009051397A9 (en) 2010-05-27
CA2701735C (en) 2012-12-11
KR101229504B1 (ko) 2013-02-04
EP2212330B1 (en) 2015-04-08
AU2008312193B2 (en) 2012-10-18
JP2011500668A (ja) 2011-01-06
BRPI0818511B1 (pt) 2021-09-21

Similar Documents

Publication Publication Date Title
MX2010004046A (es) Compuestos novedosos de mimeticos de giro inverso y su uso (3).
MA29437B1 (fr) Compose d'imidazopyridazine
MX2009011615A (es) Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados.
TN2009000439A1 (en) Substituted benzoylamino-indian-2-carboxylic acids and related compounds
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
CL2008001025A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2005079766A3 (en) Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
EP2510941A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
CL2008003933A1 (es) Compuestos derivados de n-heterociclo-[1,2-a]-piridina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
ATE491695T1 (de) Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen
EA200970639A1 (ru) Новое терапевтическое применение для лечения лейкемии
ATE428713T1 (de) Beta-strang-mimetika
CL2008003929A1 (es) Compuestos derivados de n-heterociclo-6-heterociclo-imidazo-[1,2-a]-piridin-2-carboxamida; procedimientos de preparacion; compuestos intermediarios; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neuro degenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
MY148611A (en) Imino-imidazo-pyridine derivatives having antithrombotic activity

Legal Events

Date Code Title Description
FG Grant or registration